Ganesh Wagh

Ganesh Wagh

Auto-generated profile, based on publicly available information

Ganesh Wagh

Developmental Biology, Agharkar Research Institute (ARI), Pune, Maharashtra, India

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2021 in Biology
Verified
Journal Article
Open access
PDF file
BJBhagyashri Joshi
Bhagyashri Joshi
GWGanesh Wagh
Ganesh Wagh
HKHarmandeep Kaur
Harmandeep Kaur
CPChinmoy Patra
Chinmoy Patra
Hypertension, a common chronic condition, may damage multiple organs, including the kidney, heart, and brain. Thus, it is essential to understand the pathology upon ectopic activation of the molecular pathways involved in mammalian hypertension to develop strategies to manage hypertension. Animal models play a crucial role in unraveling the disease pathophysiology by allowing incisive experimental procedures impossible in humans. Zebrafish, a small freshwater fish, have emerged as an important model system to study human diseases. The primary effector, Angiotensin II of the RAS pathway, regulates hemodynamic pressure overload mediated cardiovascular pathogenesis in mammals. There are various established mammalian models available to study pathophysiology in Angiotensin II-induced hypertension. Here, we have developed a zebrafish model to study pathogenesis by Angiotensin II. We find that intradermal Angiotensin II injection every 12 h can induce cardiac remodeling in seven days. We show that Angiotensin II injection in adult zebrafish causes cardiomyocyte hypertrophy and enhances cardiac cell proliferation. In addition, Angiotensin II induces ECM protein-coding gene expression and fibrosis in the cardiac ventricles. Thus, this study can conclude that Angiotensin II injection in zebrafish has similar implications as mammals, and zebrafish can be a model to study pathophysiology associated with AngII-RAS signaling.

1 January 2023 in Development
Verified
Journal Article
Closed access
PDF file
ARAmey Y. Rayrikar
Amey Y. Rayrikar
GWGanesh A. Wagh
Ganesh A. Wagh
MSManas K. Santra
Manas K. Santra
CPChinmoy Patra
Chinmoy Patra
Intervertebral disc (IVD) degeneration is the primary cause of back pain in humans. However, the cellular and molecular pathogenesis of IVD degeneration is poorly understood. This study shows that zebrafish IVDs possess distinct and non-overlapping zones of cell proliferation and cell death. We find that, in zebrafish, cellular communication network factor 2a (ccn2a) is expressed in notochord and IVDs. Although IVD development appears normal in ccn2a mutants, the adult mutant IVDs exhibit decreased cell proliferation and increased cell death leading to IVD degeneration. Moreover, Ccn2a overexpression promotes regeneration through accelerating cell proliferation and suppressing cell death in wild-type aged IVDs. Mechanistically, Ccn2a maintains IVD homeostasis and promotes IVD regeneration by enhancing outer annulus fibrosus cell proliferation and suppressing nucleus pulposus cell death through augmenting FGFR1-SHH signaling. These findings reveal that Ccn2a plays a central role in IVD homeostasis and regeneration, which could be exploited for therapeutic intervention in degenerated human discs.

4 February 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
CPChinmoy Patra
Chinmoy Patra
ARAmey Rayrikar
Amey Rayrikar
GWGanesh Wagh
Ganesh Wagh
FKFlorian Kleefeldt
Florian Kleefeldt
KRKaveh Roshanbinfar
Kaveh Roshanbinfar
Felix EngelFelix Engel
Felix Engel
Background: Organs and tissues need to be vascularized during development. Similarly, vascularization is required to engineer thick tissues. How vessels are formed during organogenesis is not fully understood, and vascularization of engineered tissues remains a significant challenge. Methods and Results: Here, we show that the extracellular matrix protein nephronectin is required for vascularization during zebrafish development as well as adult fin regeneration and is sufficient to promote mammalian vessel formation and maturation. Nephronectin a morphants and mutants exhibit diminished axial vein sprouting and posterior intersegmental vessel growth. Notably, the angiogenesis‐associated integrins itgav and itgb3.1 are coexpressed with nephronectin a in the region of the caudal vein plexus and posterior somites; nephronectin binds to integrin alpha‐V/integrin beta‐3.1 (ITGAV/ITGB3.1), and itgav morphants phenocopy nephronectin a mutants. In addition, nephronectin a mutants showed decreased vessel maturation compared with wild‐type siblings during caudal fin regeneration in adult zebrafish. Moreover, nephronectin promotes mammalian endothelial cell migration and tube formation in 2D and 3‐dimensional in vitro tissue culture. Further, nephronectin enhances vascular endothelial growth factor‐induced periaortic vascular capillary interconnectivity, vessel diameter, and vessel stability. Conclusions: Collectively, our results identify nephronectin as a proangiogenic factor during embryonic development, which can be used to improve the vascularization of engineered tissues.

8 August 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
AMAkanksha Mahajan
Akanksha Mahajan
RPRajesh Patil
Rajesh Patil
AJAnkita Jagtap
Ankita Jagtap
GWGanesh Wagh
Ganesh Wagh
ADAkshay Deotare
Akshay Deotare
AMAniket Mali
Aniket Mali
Triple-negative breast cancer (TNBC) is characterized by aggressive metastatic behaviour and limited therapeutic options. Here, we present a multi-tiered systems biology framework to investigate the anti-metastatic potential of enterolactone (EL), integrating computational, transcriptomic, and experimental approaches in the MDA-MB-231 TNBC model. Network pharmacology identified 78 EL-metastatic TNBC (mTNBC) overlapping targets as potential therapeutic targets of EL against mTNBC, with PPI and GMFA network enrichment uncovering key metastasis-associated pathways including Notch, TGF-β, TNF, and ErbB signaling. Molecular docking and 100 ns molecular dynamics simulations revealed stable binding of EL to several core oncogenic proteins (e.g., EGFR, PARP1, AURKB, SMAD4, CDK4), suggesting poly-pharmacological engagement. Genome-wide transcriptomic profiling of EL-treated cells coupled with GSEA revealed coordinated downregulation of oncogenic programs including E2F, G2/M checkpoint, MYC targets, EMT, and metabolic plasticity, alongside induction of NRF2 signaling and ferroptosis. This study reports, for the first time, transcriptome-wide effects of EL in MDA-MB-231 cells, linking its activity to the repression of stemness, invasion, and immune-evasive traits. Experimental validation via qPCR confirmed EL-mediated suppression of key molecular targets of TGF-β and Notch signaling pathways. EL also impaired cortactin expression and disrupted cytoskeletal remodeling, validated by immunofluorescence and flow cytometry studies, indicating attenuation of invasive machinery. Furthermore, EL reduced metastatic dissemination in a zebrafish xenograft model, reinforcing its in vivo anti-metastatic potential. Together, our integrative study elucidates EL's multitarget mechanism against metastatic TNBC and highlights its translational promise as a systems-level modulator of oncogenic signaling. These findings warrant further in-depth mechanistic investigations to validate EL's therapeutic potential.